
Sign up to save your podcasts
Or


Despite the challenges of managing rheumatoid arthritis—especially for patients with difficult-to-treat cases or a history of cancer—clinical trials, updated guidelines, and data-driven decision-making are helping to shape the future of care. Dive deeper into how rheumatoid arthritis treatment is evolving with Dr. Robin Dore, board-certified rheumatologist and Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
Rheumatoid arthritis presents uniquely in every patient, which can make treatment decisions complex. As a result, it’s important to balance factors like symptom variations, patient concerns, and medical guidelines to find the right approach. Hear how risk-benefit discussions and evolving treatment strategies can shape care from Dr. Robin Dore, a board-certified rheumatologist and an Invited Lecturer at the University of California, Irvine in the Division of Rheumatology.
In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of tenosynovial giant cell tumors (TGCT). Topics include differentiating TGCT by presentation; surgical candidacy, approaches, and limitations; systemic treatment options with CSF1R inhibitors; and considerations for treatment selection with surgical, nonsurgical, or combination interventions. A patient case example is used to demonstrate optimal multidisciplinary and patient-centered treatment considerations and selection. Strategies for multidisciplinary collaboration to ensure comprehensive monitoring and effective disease management are also explored. Tune in to find out how to enhance the collaborative capacity of multidisciplinary teams in developing individualized, patient-centered treatment plans for patients with TGCT.
Vimseltinib is now FDA-approved for adult patients with symptomatic TGCT, for which surgical resection will potentially cause worsening functional limitation or severe morbidity. This activity was recorded prior to this FDA approval.
With at least 4 percent of patients who experience COVID-19 developing long COVID, improving care for post-infectious chronic conditions is critical. By prioritizing research and education on the rheumatological effects of acute infections, we can address these patients’ unmet needs. Join Dr. Leonard Calabrese, Vice Chairman of the Department of Rheumatic and Immunologic Disease and Head of Clinical Immunology at the Cleveland Clinic Foundation, as he explains what we know so far about these conditions.
Managing psoriasis, psoriatic arthritis, and axial spondyloarthritis with ixekizumab may cause adverse effects in patients. That’s why a recent research review further investigated the safety of this treatment over time, analyzing data from 25 clinical trials and noting common side effects. Learn more about ixekizumab’s long-term use with Dr. Atul Deodhar, the lead author of this study. He’s also a Professor of Medicine and the Medical Director of Rheumatology Clinics at Oregon Health & Science University.
Chronic pain isn’t always caused by inflammation—in rheumatic conditions, nociplastic and neuropathic pain can both complicate treatment. Understanding these pain types is crucial to effective patient management. Dr. Philip Mease, Director of Rheumatology Research at Swedish Medical Center in Seattle and Clinical Professor at the University of Washington School of Medicine, explains the complexities behind each type of pain and key considerations for patient care.
Managing pain in chronic rheumatic conditions requires a comprehensive approach. Through education and innovative research, we can develop more effective ways to care for patients. Dr. Philip Mease, Director of Rheumatology Research at Swedish Medical Center and Clinical Professor at the University of Washington School of Medicine, gives a preview into the future of pain management.
Menopause accelerates bone loss due to declining estrogen levels, increasing the risk of osteoporosis and fractures. To learn how we can best support bone health during this transition, CEO of the Bone Health and Osteoporosis Foundation Claire Gill speaks with Dr. Andrea Singer, Chief Medical Officer of the Bone Health and Osteoporosis Foundation, Professor of Medicine and Obstetrics and Gynecology at MedStar Georgetown University Hospital, and a member of the National Menopause Foundation's Medical Advisory Committee.
This program contains important information about the limitations of current therapies used to treat plaque psoriasis. Drs. Kim Papp and Jerry Bagel discuss these shortcomings and outline clinical data on investigational oral medications for plaque psoriasis.
In light of the opioid epidemic, the use of cannabis for therapeutic purposes is becoming of interest. But since there are other alternatives that are often more effective and have better safety profiles, it’s important to understand the evidence and guideline recommendations around these two treatment options. Here to share key considerations for using opioids and cannabis to treat patients living with chronic pain is Dr. Jason Busse, who presented a session on this exact topic at the 2024 Congress of Clinical Rheumatology.